Navigation Links
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
Date:3/25/2010

Researchers at the Eastern Virginia Medical School Strelitz Diabetes Center have been awarded a $1,076,250 grant by the Department of Defense (DoD) Peer Reviewed Medical Research Program to develop new ways of reversing the underlying causes of Type 1 diabetes.

David Taylor-Fishwick, PhD, associate professor of internal medicine and director of the Cell, Molecular and Islet Biology Laboratory, leads the team whose research applies to both regenerative and autoimmune medicine.

"Type 1 diabetes is caused by an autoimmune attack that destroys the insulin-producing beta cells, and the body does not automatically regenerate or replace these cells," explains Dr. Taylor-Fishwick. "The unique challenge in reversing Type 1 diabetes is to regenerate the insulin-producing beta cells and to stop the body's autoimmune attack."

Insulin is the hormone that helps the body convert glucose from food into energy. When the beta cells are destroyed, no insulin can be produced. Insulin replacement therapy helps the body maintain normal glucose levels, but doesn't prevent the serious diabetes health problems such as blindness, nerve damage, heart disease and kidney failure.

Dr. Taylor-Fishwick's research on beta cell regeneration has focused on INGAP (Islet Neogenesis Associated Protein), branded as Exsulin, the breakthrough discovery made by Aaron I. Vinik, PhD, MD, director of research at the Strelitz Diabetes Center, and Dr. Lawrence Rosenberg of McGill University. Published trials of Exsulin demonstrated promising results in both Type 1 and Type 2 diabetes patients.

The DoD grant will fund the next phase in the team's research finding a way to neutralize the immune system's attack of the beta cells. This immune attack occurs at the onset of diabetes and may continue after Type 1 diabetes has appeared. The benefits of this research may also apply to other autoimmune diseases such as lupus and rheumatoid arthritis.

Dr. Taylor-Fishwick and his team will test several experimental drugs developed by Jerry Nadler, MD, chair of internal medicine and director of the EVMS Strelitz Diabetes Center. The compounds are designed to modify the autoimmune response and stabilize beta cells. The goal is to develop these compounds into an oral pill.

"The Department of Defense, through its Congressionally Directed Medical Research Program, is especially interested in research to combat autoimmunity," Dr. Taylor-Fishwick says. "So part of our work is to block the process of autoimmunity that occurs in diabetes. We are using a drug called Lisofylline (LSF) and related molecules to block interleukin-12, a protein that triggers the autoimmune response," he explains. "By targeting interleukin-12 signaling, we hope to redirect the immune system, but not wipe it out."

The researchers hope that one of these compounds, when used in conjunction with Exsulin, may help to create a combination therapy regimen that could achieve a functional cure for Type 1 diabetes.


'/>"/>

Contact: Jina Gaines
gainesjn@evms.edu
757-446-7070
Eastern Virginia Medical School
Source:Eurekalert  

Related medicine news :

1. US Wellness, Inc. Receives National Recognition for Laboratory Excellence
2. American Public Health Champion Receives 2010 Stockholm Water Prize
3. Society for New Communications Research Receives Grant to Help Raise Awareness and Reduce Racial and Ethnic Health Disparities
4. BUSM researcher receives prestigious young investigator award
5. Yondelis(R) Receives Five New Approvals Outside the European Economic Area
6. Christiana Care Health Systems Darcy Burbage Receives Oncology Nursing Society Award
7. Moleac Receives BioSpectrum Asia Emerging Company of the Year 2010 Award
8. CoreObjects Receives Project Management Institutes Excellence Award for Diabetes Contribution
9. Zimmer Receives Recognition for Health Economics Data Presented at 77th Annual American Academy of Orthopaedic Surgeons Meeting
10. U.S. Senator Kit Bond Receives 2010 AOA Health Care Leadership Award
11. Intellimed's Popular Data Reporting Software IM-IC (Intelligent Client) Receives Latest Update
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EVMS receives more than $1 million in federal funds to develop new ways to reverse type 1 diabetes
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... ... May 26, 2017 , ... A new analysis of community health data ... are located in the Midwest. With the average cost of healthcare rising and the ... with both the quality and affordability of where they live. An annual 2017 report ...
(Date:5/26/2017)... ... May 26, 2017 , ... via seating is proud to ... task chair specifically designed for clinical areas. Genie Copper Mesh is a crossover ... Cupron® to provide customers with a game changing chair that is affordably priced,” ...
(Date:5/26/2017)... ... ... After raising nearly $30,000 on Kickstarter , about three-times its original campaign ... crowdfunding price on Indiegogo . , “Along with creating an anti-stress gadget to ... fidget toy to the market that was made of superior quality and wouldn’t break ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... Silver Birch ... community, which is located on more than four acres of land at 5620 Sohl ... , The 103,000 square-foot building includes 125 studio and one-bedroom apartments. Each of ...
Breaking Medicine News(10 mins):
(Date:5/6/2017)... , May 5, 2017   Provista , a proven ... than 200,000 customers, today announced Jim Cunniff as ... of executive and business experience to Provista, including most recently ... in California . He assumed his new ... is a great fit for Provista," says Jody Hatcher ...
(Date:5/4/2017)... Tenn. , May 4, 2017  A ... Infection Control, Ultraviolet-C light as a ... Tru-D SmartUVC,s ability to reduce bioburden on anesthesia ... bioburden reduction on high-touch, complex medical equipment surfaces ... surgical infections. "This study further validates ...
(Date:5/4/2017)... May 4, 2017  A new tight-tolerance microextrusion ... other highly-engineered materials, is being launched by Natvar, ... been developed in recent years to service a ... surgical applications. More expensive materials such as glass ... tubing due to their ability to consistently hold ...
Breaking Medicine Technology: